Two companies, one in California and the other in Michigan, are the latest to receive warning letters about CBD from the U.S. Food and Drug Administration.
The warnings posted Monday accuse BioLyte Laboratories of Grand Rapids, Michigan, and Honest Globe of Santa Ana, California, of selling CBD pain relief products over the counter, a violation of federal law.
“No CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use,” the FDA told Honest Globe.
BioLyte was warned that CBD can’t be sold even as an inactive ingredient. The agency noted that BioLyte’s label mentioned “pain relief cream with rejuvenating CBD.”
The companies must respond within 15 days.
The FDA’s latest CBD warnings come two months after the agency withdrew suggested CBD regulations that were awaiting White House review.
President Joe Biden has yet to name a permanent FDA commissioner; Dr. Janet Woodcock has been serving as acting commissioner since Jan. 20.
Medical Disclaimer:
The information provided in these blog posts is intended for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The use of any information provided in these blog posts is solely at your own risk. The authors and the website do not recommend or endorse any specific products, treatments, or procedures mentioned. Reliance on any information in these blog posts is solely at your own discretion.
